Do we need all that emicizumab?

Early View

LETTER TO THE EDITOR

Anna-Elina Lehtinen,

Anna-Elina Lehtinen

Helsinki University Hospital, Coagulation Disorders Unit, Department of Haematology, Comprehensive Cancer Centre, Helsinki, Finland

Search for more papers by this authorRiitta Lassila,

Corresponding Author

Riitta Lassila

Helsinki University Hospital, Coagulation Disorders Unit, Department of Haematology, Comprehensive Cancer Centre, Helsinki, Finland

Program Unit for Systems Oncology, University of Helsinki, Helsinki, Finland

Correspondence

Riitta Lassila, University of Helsinki, Program Unit for Systems Oncology, Helsinki, Finland.

Email: riitta.lassila@kolumbus.fi

Search for more papers by this author PDFPDF Please review our Terms and Conditions of Use and check box below to share full-text version of article.

I have read and accept the Wiley Online Library Terms and Conditions of Use

Shareable Link

Use the link below to share a full-text version of this article with your friends and colleagues. Learn more.

Share a link

Share on

No abstract is available for this article.

留言 (0)

沒有登入
gif